Research programme: genetically engineered paraxonase 1 protein complex - BioLineRx
Alternative Names: BL 3050Latest Information Update: 16 Jul 2016
At a glance
- Originator Yeda Research and Development Company Ltd
- Class
- Mechanism of Action Enzyme modulators; Protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Atherosclerosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Atherosclerosis in Israel
- 28 Mar 2007 Preclinical trials in Atherosclerosis in Israel (unspecified route)